(PRWEB) June 26, 2013
New Oral Anticoagulants Markets

TriMarkPublications.com cites in its newly published New Oral Anticoagulants Markets report that the global anticoagulants market place will spike to over $ 24 billion by 2019.
Anticoagulants decrease the capacity of the blood to create harmful blood clots that can in the end lead to a heart attack or stroke. Even though at times referred to as blood thinners, they do not truly thin the blood and only assist avoid the formation of new blood clots.

Anticoagulants can be categorized into 5 major modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and element Xa inhibitors. For much more than 50 years and till not too long ago, the only oral anticoagulants have been vitamin K antagonists such as warfarin. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and other new oral anticoagulants have a number of advantages over warfarin, including no periodical laboratory monitoring and far more predictable effects with fixed doses.

The U.S. anticoagulants marketplace, which encompasses more than 60% of the worldwide industry for anticoagulants, will grow from $ 7.06 billion in 2012 to $ 15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to as soon as-daily oral anticoagulants.

New Oral Anticoagulants Markets offers a thorough overview of these and other new oral anticoagulants, their authorized indications, drug profiles, pharmacokinetic parameters and the respective regions of marketplace growth.

The report also examines businesses manufacturing anticoagulant equipment and supplies in the globe. Firms covered incorporate: Akers, Anthera, ARYx, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Medicines Business, Medicure, Merck, Novartis, Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi. Detailed charts with sales forecasts and marketshare data are incorporated.

New Oral Anticoagulants Markets Table of Contents:

1. Introduction 
1.1 Scope of this Report 
1.2 Methodology 
1.3 Executive Summary 
two. An Overview of Anticoagulants 
2.1 Scope of this Chapter 
2.1.1 Unmet Health-related Requirements with Existing Anticoagulants 
2.1.two Pharmacology of Injectable Anticoagulants 
2.1.3 Marketed and Registered Drugs for Anticoagulation and Related Disorders 
2.two Oral Anticoagulants 
two.two.1 Potential Limitations of New Oral Anticoagulants 
2.2.two Desired Attributes of Anticoagulants 
2.2.3 Comparison of New Anticoagulants 
two.2.four Bleed Rates of New Anticoagulants 
three. Selected Oral Anticoagulants 
3.1 Warfarin 
three.1.1 Warfarins Location in Clinical Therapy 
three.1.2 Drug Interaction with Warfarin 
3.1.3 Warfarins Interactions with Meals 
three.1.four Interactions of Warfarin with Dietary Vitamin K 
3.2 Dabigatran (Pradaxa) 
three.two.1 Use of Dabigatran in Particular Scenarios 
3.two.two Measuring the Anticoagulant Impact of Dabigatran 
three.2.three Activated Partial Thromboplastin Time (aPTT) 
3.two.four Thrombin Time (TT) and Hemoclot 
3.2.five Ecarin Clotting Time (ECT) 
three.two.six Prothrombin Time (PT) and INR 
three.two.7 Measures for Overdose 
three.2.8 Management of Bleeding Complications 
3.two.9 For Patients Undergoing Surgical Intervention 
3.two.ten For Dental Interventions 
three.2.11 For Spinal Anesthesia/Epidural Anesthesia/Lumbar Puncture 
3.2.12 For Individuals with Acute Coronary Syndrome (ACS) 
three.two.13 Cardioversion in Dabigatran Treated Individuals 
3.two.14 For Sufferers with Stroke 
three.two.15 Dabigatran right after Ischemic Stroke 
three.two.16 Strengths and Weaknesses of Dabigatran 
three.2.16.1 Strengths of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics 
3.two.16.two Weaknesses of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics 
three.two.16.three Strengths of Dabigatran in Laboratory Monitoring 
three.2.16.four Weaknesses of Dabigatran in Laboratory Monitoring 
three.2.16.5 Strengths of Dabigatran in Clinical Efficacy 
three.2.16.six Weaknesses of Dabigatran in Clinical Efficacy 
3.2.16.7 Strengths of Dabigatran in Controlling Bleeding 
three.two.17 Comparison of Dabigatran and Rivaroxaban in Sites of Action 
three.3 Rivaroxaban (Xarelto) 
three.3.1 Dosage and Administration 
3.three.2 Risk of Stroke right after Discontinuation in Non-Valvular Atrial Fibrillation 
3.three.three Threat of Bleeding 
3.3.4 Bleeding Events in ROCKET AF Trial 
3.three.5 Bleeding Events in RECORD Trial 
3.three.6 Overdosage 
3.three.7 Mechanism of Action 
3.three.8 Comparable Efficacy of Rivaroxaban 
three.three.9 Prophylaxis of Deep Vein Thrombosis 
three.four Eliquis (Apixaban) 
3.4.1 AVERROES Results 
3.5 Edoxaban 
3.six Betrixaban 
3.7 Pipeline Agents 
3.8 Comparison of Oral Anticoagulants 
three.9 Heparins 
3.10 Dalteparin (Fragmin) 
3.11 Enoxaparin (Lovenox) 
three.11.1 Indications and Usage 
3.11.2 Percutaneous Coronary Revascularization Procedures 
3.11.three Use of Lovenox with Concomitant Health-related Circumstances 
three.11.3.1 Thrombocytopenia 
three.11.three.2 Interchangeability with Other Heparins 
three.11.3.three Pregnant Ladies with Mechanical Prosthetic Heart Valves 
3.11.three.four Laboratory Tests 
three.11.three.5 Pharmacodynamics 
three.11.3.6 Pharmacokinetics 
three.12 Fondaparinux (Arixtra) 
3.13 Tinzaparin (Innohep) 
three.14 Semuloparin Sodium (AVE5026) 
3.15 Idrabiotaparinux 
three.16 Otamixaban 
three.17 RB006 
three.18 Reversal Agents and Antidotes 
3.18.1 Vitamin K 
3.18.2 Recombinant Factor VIIa 
3.18.three Prothrombin Complex Concentrates 
four. A Short Overview of Antiplatelets 
four.1 Overview of this Chapter 
four.1.1 Differences between Antiplatelets and Anticoagulants 
4.1.2 Need to have for Antiplatelets 
four.1.3 Side Effects of Antiplatelets 
four.1.4 Selecting an Antiplatelet 
four.1.five Part of Platelets in Thrombosis 
four.1.6 Inhibitors of Platelet Adhesion 
4.1.7 Inhibitors of Platelet Activation 
four.1.7.1 Inhibitors of TXA2 Pathway 
four.1.7.two Inhibitors of P2Y12 
four.1.7.three PAR-1 Inhibitors 
four.1.7.four Phosphodiesterase Inhibitors 
4.two Antiplatelet Drugs 
4.two.1 Aspirin 
four.two.2 Aggrenox 
four.two.3 Ticagrelor (Brilinta) 
four.2.4 Clopidogrel (Plavix) 
4.2.4.1 Indications and Usage 
4.two.four.2 Basic Risk of Bleeding 
four.two.5 Effient (Prasugrel) 
5. Coagulation Assays 
5.1 Clotting Assays 
five.1.1 Chromogenic Approaches 
5.1.2 Prothrombin Time 
5.1.three Activated Partial Thromboplastin Time 
5.1.4 Thrombin Time 
5.1.five Fibrinogen (Clauss Strategy) 
five.1.six Derived Fibrinogen 
5.1.7 Antithrombin 
five.1.eight Protein C 
five.1.9 Protein S 
five.1.10 Lupus Anticoagulants 
five.1.11 ProC International Assay and APC Resistance (APCR) 
5.two Influence of New Anticoagulants on Coagulation Assays 
6. Disease Conditions Targeted by Anticoagulants 
6.1 Cardiovascular Diseases 
6.1.1 Stroke 
6.1.2 Ischemic Stroke 
6.1.3 Hemorragic Stroke 
six.1.4 Subarachnoid Hemorrage 
six.1.five Worldwide Incidence and Prevalence of Stroke 
six.1.6 Incidence of Stroke in the U.S. 
six.1.7 Mortality from Heart Illness and Stroke i
